How Botox works (and why your second round sometimes doesn't)

What Botox actually is

Botox is not a peptide: it is a 1,295-amino-acid protein made by the bacterium Clostridium botulinum, roughly 100 times bigger than a typical therapeutic peptide, though it disables nerves the same way many peptides do. Dysport, Xeomin, Daxxify, and Letybo are sibling brands built on the same toxin, differing mainly in formulation and how long they last.

You've seen the brand name everywhere. Underneath it, Botox is a really big molecule made by a bacterium called Clostridium botulinum, yes, the same one behind food-poisoning botulism. Used in microscopic, purified amounts, the same toxin becomes the world's most studied wrinkle-relaxer.

So is it a peptide? Technically, no. Peptides are short chains of building blocks (called amino acids), usually under 50 of them. Botox is a 1,295-link chain [1], which biologists call a protein, not a peptide. It's roughly 100 times the size of a typical small peptide, but it talks to your nerves the same way many therapeutic peptides do, which is why it ends up in the same conversation.

The brand-name landscape: Botox is the original (FDA-approved 2002). Dysport and Xeomin are sibling brands with slightly different purification. Daxxify (2022) is the newest, with a tweaked formulation that lasts longer. Letybo (2024) is the cheapest first-timer option. All of them work through the same mechanism in the next section.

How Botox paralyzes a muscle (the three moves)

Botox blocks a nerve's chemical messenger in three moves: it binds only to nerve endings next to a muscle, then its molecular scissors cut one rope, a protein called SNAP-25, from the three-rope SNARE system nerves use to fire. Without that rope acetylcholine cannot release, so the muscle relaxes for three to four months and the wrinkles it caused soften.

Your nerves talk to your muscles by passing a tiny chemical messenger across a gap. Botox jams that messenger system. Picture it in three moves.

Move 1: the toxin boards the nerve. A nerve ending sits right next to a muscle. Botox finds that nerve ending and gets pulled inside, the way a key fits a lock and turns. This part is so specific that botulinum toxin only enters nerve cells: it ignores almost everything else in your body.

Move 2: it cuts one specific rope. The nerve uses a small rope-and-pulley system to release its messenger. Botox carries molecular scissors that snip one specific rope, a protein called SNAP-25, part of a three-rope system biologists named SNARE [2]. Different botulinum types cut different ropes: type A (regular Botox) cuts SNAP-25, and that turns out to be the most stable cut, which is why type A lasts the longest.

Move 3: the message never arrives. Without that rope, the nerve can't release its messenger (called acetylcholine, the chemical that tells the muscle to contract). The muscle stays relaxed for as long as the rope stays cut, which for type A is roughly three to four months. Wrinkles caused by that muscle's repeated contraction soften, because the muscle isn't pulling on the skin anymore.

Why Botox wears off

The rope grows back. A nerve cell constantly makes fresh SNAP-25 and sprouts new nerve endings that bypass the cut, so within three to four months the messenger flows again and the muscle moves like before, which is why touchup appointments exist. The effect ages out on a fixed clock, though some people metabolize the toxin faster than others.

The rope grows back. Your nerve cell is constantly making fresh SNAP-25 protein, and within a few weeks it also starts growing brand-new little sprouts that bypass the cut entirely. By month three or four, enough new rope is in place that the messenger flows again and the muscle moves like before [3]. That's the whole reason touchup appointments exist.

This also explains why Botox is reversible. Unlike a surgical cut, the toxin's effect ages out on a clock you can't really speed up or slow down. Some people metabolize it faster (heavy weightlifters, hyperactive facial muscles, very small initial doses) and feel results fade by month two. Most people land in the three-to-four-month range, with a fairly consistent rhythm once they've had a few rounds.

Why your second round of Botox sometimes works worse

About one to two percent of long-term users stop responding to Botox, a phenomenon called tachyphylaxis: their immune system builds neutralizing antibodies that intercept the toxin before it reaches the nerve, so injections land but produce no visible effect. Frequent high doses, short treatment intervals, and brand-switching raise the risk, and antibodies rarely disappear once formed.

Here's the part nobody at the medspa volunteers. About 1 to 2 percent of long-term users stop responding to Botox over time [4]. Their immune system has learned to recognize the toxin as a foreign invader and built defenses against it (the medical name is tachyphylaxis, a fancy term for the body learning to neutralize the drug). The body makes neutralizing antibodies that lock onto Botox before it can reach the nerve, so the injection lands but does nothing visible.

A few things make this more likely: very high doses repeated frequently, very short intervals between treatments (under three months), and switching between brands and back in a way that exposes the immune system to slightly different forms of the same toxin. Genetics plays a role too: computational modeling of how the toxin's surface interacts with different immune-system (HLA) gene variants found that some people's HLA profile binds the toxin's antibody-triggering regions more readily than others, which may help explain why only a minority of long-term users ever develop resistance [5]. Once antibodies form they don't reliably go away, though some people regain partial response after a long break or by switching to a different serotype like type B (sold as Myobloc / Neurobloc).

The practical takeaway: if you've been getting injections every couple of months for years and notice they're working less, it's not in your head, and it's probably not the injector. Ask about an antibody screen, and consider a longer rest interval before switching products.

The new generation: Daxxify, Letybo, and what's next

Daxxify (2022) pairs the same toxin with a stabilizer peptide, and phase 3 trials showed a median six months of effect, at a higher price and less tracking history. Letybo (2024) is a cheaper, faster-onset option lasting the usual three to four months, and Xeomin strips out extra protein to lower antibody risk. All four share the same SNARE-cutting mechanism.

Botox got FDA approval for cosmetic use in 2002. For two decades it had no real competitor on duration. Then Daxxify arrived in 2022: same active toxin, but mixed with a stabilizer molecule (a 35-amino-acid peptide) that helps the nerve hold onto the toxin longer. Phase 3 trials showed a median 6 months of frown-line reduction, with some patients reporting effect at 9 months [6]. The trade-off is a higher per-treatment price, a smaller real-world tracking record, and slightly higher reported antibody rates in early data.

Letybo (FDA-approved 2024) is a Korean-developed product positioned as a cheaper, faster-onset alternative aimed at first-timers, with duration around the traditional 3 to 4 months. Xeomin is a "naked" formulation that strips out the protein scaffolding the toxin normally travels with; in theory this lowers antibody risk, though in practice the difference for real users is debated. All four work through the same SNARE-cutting mechanism described above; they differ mostly in how long they last and how immunogenic they are.

Topical "Botox" peptides: do they work?

Argireline, the peptide behind most needle-free botox serums, targets the same SNAP-25 rope as an injection and shows roughly 30 percent wrinkle-depth reduction over a month in small studies. The catch is delivery: only 0.2 to 0.3 percent of a topical dose crosses skin, so it works best as a slow daily maintenance ingredient, not a substitute for injections.

Walk into Sephora and you'll see serums advertising "Botox in a bottle" or "needle-free wrinkle smoothing." The most common ingredient behind those claims is a peptide called Argireline (chemical name acetyl hexapeptide-8). It works on the same SNAP-25 rope Botox targets: it's literally a tiny piece of SNAP-25 designed to gum up the rope-and-pulley system from inside [7]. Small studies show wrinkle-depth reductions around 30 percent over a month of daily use. That is meaningful, but it's a small fraction of what an injection does.

The bigger problem is delivery. Your skin's outer layer is engineered to keep things out. When researchers measured how much of a topical Argireline product actually crosses that barrier, the answer was around 0.2 to 0.3 percent [8]: the rest sits on the surface and eventually washes off. So a "10 percent Argireline serum" is really delivering closer to 0.02 percent of its labeled active ingredient to the muscle. That's why the published wrinkle-reduction numbers are real, but modest.

Verdict: Argireline serums are best thought of as a daily maintenance ingredient that compounds slowly over months, not as a substitute for an injection. They pair reasonably with copper peptides (like GHK-Cu) and retinoids, which work on different mechanisms (collagen synthesis and cell turnover), so they don't compete for the same target. If you want a practical protocol for combining GHK-Cu with the rest of your skincare routine, the GHK-Cu layering guide covers the timing and ingredient conflicts in detail. They are not equivalent to Botox, despite what the bottle says.

Medical uses beyond wrinkles

Beyond wrinkles, the FDA has approved Botox for chronic migraine, excessive sweating, eye-twitching, neck spasms, an overactive bladder, and crossed eyes, always via the same nerve-blocking mechanism. Its newest use is R-CPD, the inability to burp, a condition Reddit communities helped surface, where recent pediatric data shows the injection working on the first try about 80 percent of the time.

Botox treats more than crow's feet. The FDA has approved it for chronic migraine (more than 15 headache days per month, with strong real-world effectiveness data [9]), excessive armpit sweating (hyperhidrosis), the eye-twitch condition called blepharospasm, neck-muscle spasms (cervical dystonia), an overactive bladder, and crossed eyes (strabismus). The mechanism is identical: the muscle relaxes wherever the toxin is placed.

The most surprising recent application is R-CPD (retrograde cricopharyngeal dysfunction), the inability to burp. For decades it was barely recognized: people lived for years with chest pressure after eating and never knew there was a name for it. Reddit communities surfaced the diagnosis around 2018 to 2020, and clinicians started treating it with Botox injections into a small upper-throat muscle that fails to relax during a normal burp. Recent pediatric outcome data shows the injection works in roughly 80 percent of cases on the first try [10]. The full biology behind the condition, and what the Botox procedure involves, is explained in the guide to why some people can't burp. One molecule, one mechanism, lots of muscles.

What the evidence actually says (an honest grade)

Grading the evidence honestly: cosmetic wrinkle reduction and chronic migraine prevention both rest on strong, decades-deep randomized trial data. Daxxify's six-month duration claim is moderate, since the headline figure includes dropouts. Argireline matching an injection is weak evidence: small, often industry-sponsored, with no injection control. Reversing antibody resistance by switching serotypes is weak to moderate, based mainly on case reports.

For cosmetic frown lines and crow's feet, the evidence is strong: decades of randomized controlled trials with consistent results. For chronic migraine prevention, also strong, with PREEMPT trials and replicated real-world cohorts. For Daxxify lasting six months, the evidence is moderate: the headline median number includes patients who dropped out for various reasons, and real-world durations may be a touch shorter than the trial figure. For Argireline matching Botox, weak: the studies that say so are small, often industry-sponsored, and rarely measure against an actual injection control. For switching toxin serotypes to reverse tachyphylaxis, weak to moderate, mostly case reports and small series.

Nothing in this article should make you avoid an injection if a board-certified dermatologist or plastic surgeon recommends one for a specific issue. The goal here is to make you a more informed patient, so when the medspa says "Botox is just Botox," you know to ask which serotype, which formulation, what dose, and what they expect for duration in your specific muscle group. For the broader picture of collagen degradation that Botox alone does not address, the glycation and aging guide covers how cumulative sugar damage stiffens the same dermal collagen that Botox relaxes the overlying muscle from.